The COVID-19 pandemic has put healthcare infrastructures and our social and economic lives under unprecedented strain. Effective solutions are needed to end the pandemic while significantly lessening its further impact on mortality and social and economic life. Effective and widely-available vaccines have appropriately long been seen as the best way to end the pandemic. Indeed, the current availability of several effective vaccines are already making a significant progress towards achieving that goal. Nevertheless, concerns have risen due to new SARS-CoV-2 variants that harbor mutations against which current vaccines are less effective. Furthermore, some individuals are unwilling or unable to take the vaccine. As health officials across the globe scramble to vaccinate their populations to reach herd immunity, the challenges noted above indicate that COVID-19 therapeutics are still needed to work alongside the vaccines. Here we describe the impact that neutralizing antibodies have had on those with early or mild COVID-19, and what their approval for early management of COVID-19 means for other viral entry inhibitors that have a similar mechanism of action. Importantly, we also highlight studies that show that therapeutic strategies involving various viral entry inhibitors such as multivalent antibodies, recombinant ACE2 and miniproteins can be effective not only for pre-exposure prophylaxis, but also in protecting against SARS-CoV-2 antigenic drift and future zoonotic sarbecoviruses.

中文翻译：

---

避开！SARS-CoV-2 进入抑制剂：它们作为 COVID-19 疗法的作用和效用

COVID-19 大流行使医疗保健基础设施以及我们的社会和经济生活面临前所未有的压力。需要有效的解决方案来结束这一流行病，同时显着降低其对死亡率和社会经济生活的进一步影响。长期以来，有效且广泛可用的疫苗一直被视为结束大流行的最佳方式。事实上，目前可用的几种有效疫苗已经在实现这一目标方面取得了重大进展。然而，由于新的 SARS-CoV-2 变体包含突变，目前的疫苗对其无效，因此人们的担忧有所增加。此外，有些人不愿意或不能接种疫苗。随着全球卫生官员争先恐后地为其人口接种疫苗以达到群体免疫，上述挑战表明，仍需要 COVID-19 疗法与疫苗一起发挥作用。在这里，我们描述了中和抗体对早期或轻度 COVID-19 患者的影响，以及它们对 COVID-19 早期管理的批准对具有类似作用机制的其他病毒进入抑制剂意味着什么。重要的是，我们还强调了一些研究，这些研究表明，涉及各种病毒进入抑制剂（如多价抗体、重组 ACE2 和小蛋白）的治疗策略不仅可以有效地进行暴露前预防，还可以有效地防止 SARS-CoV-2 抗原漂移和未来人畜共患的sarbecoviruses。在这里，我们描述了中和抗体对早期或轻度 COVID-19 患者的影响，以及它们对 COVID-19 早期管理的批准对具有类似作用机制的其他病毒进入抑制剂意味着什么。重要的是，我们还强调了一些研究，这些研究表明，涉及各种病毒进入抑制剂（如多价抗体、重组 ACE2 和小蛋白）的治疗策略不仅可以有效地进行暴露前预防，还可以有效地防止 SARS-CoV-2 抗原漂移和未来人畜共患的sarbecoviruses。在这里，我们描述了中和抗体对早期或轻度 COVID-19 患者的影响，以及它们对 COVID-19 早期管理的批准对具有类似作用机制的其他病毒进入抑制剂意味着什么。重要的是，我们还强调了一些研究，这些研究表明，涉及各种病毒进入抑制剂（如多价抗体、重组 ACE2 和小蛋白）的治疗策略不仅可以有效地进行暴露前预防，还可以有效地防止 SARS-CoV-2 抗原漂移和未来人畜共患的sarbecoviruses。